A 38-year-old woman presents to the gynaecology clinic with complaints of heavy menstrual bleeding for the past 8 months and progressive abdominal distension. She reports passage of clots and dysmenorrhoea. On examination, the uterus is enlarged, firm, and irregular with a mass palpable in the lower abdomen. Haemoglobin is 8.2 g/dL. Transvaginal ultrasound shows multiple hypoechoic lesions within the myometrium with heterogeneous echotexture, some with cystic degeneration. What is the most appropriate first-line medical management for this patient?

Explanation

## Management of Symptomatic Fibroid Uterus with Heavy Menstrual Bleeding ### Clinical Context This 38-year-old woman presents with symptomatic uterine fibroids: heavy menstrual bleeding with clots, dysmenorrhoea, progressive abdominal distension, an enlarged irregular uterus with a palpable lower abdominal mass, and anaemia (Hb 8.2 g/dL). Transvaginal ultrasound confirms multiple intramural fibroids with degenerative changes. ### First-Line Medical Management **Key Point:** In a patient with symptomatic fibroids causing significant menorrhagia, anaemia, and a large palpable uterine mass, **GnRH agonists** (e.g., leuprolide, goserelin) are the most appropriate first-line medical management. They induce a hypoestrogenic state, leading to fibroid shrinkage (up to 30–50%), reduction in uterine volume, and temporary amenorrhoea — allowing correction of anaemia and reassessment for definitive therapy. ### Why GnRH Agonist is the Correct Answer Here | Feature | GnRH Agonist | LNG-IUD | Hysterectomy | Myomectomy | |---------|-------------|---------|--------------|------------| | **Reduces fibroid size** | Yes (30–50%) | No | N/A | Yes (removes) | | **Controls heavy bleeding** | Yes (amenorrhoea) | Yes (but less reliable with large/multiple fibroids) | Yes | Yes | | **Corrects anaemia** | Yes, rapidly | Slower onset | Yes | Yes | | **Suitable for large/multiple fibroids** | Yes | Limited (cavity distortion reduces efficacy) | Yes | Yes | | **First-line medical option** | Yes | Second-line in this context | No (surgical) | No (surgical) | | **Duration** | 3–6 months (bridging) | 5 years | Permanent | Variable | **High-Yield:** GnRH agonists are the preferred first-line medical therapy for symptomatic fibroids with significant mass effect, large uterine size, and anaemia. They are used for 3–6 months to shrink fibroids, correct anaemia, and facilitate subsequent surgery if needed (ACOG Practice Bulletin No. 228; Shaw RW, *Fibroid Uterus*, in Shaw's Textbook of Gynaecology). ### Why LNG-IUD is NOT the Best Answer Here **Clinical Pearl:** The LNG-IUD is effective for menorrhagia in women with small-to-moderate fibroids and a normal or near-normal uterine cavity. However, in this patient: - Multiple fibroids with cystic degeneration and significant uterine enlargement (palpable abdominal mass) suggest cavity distortion, which reduces LNG-IUD efficacy and may preclude insertion. - LNG-IUD does **not** reduce fibroid size or address the mass effect. - It is not the preferred option when fibroids are large, multiple, or associated with significant abdominal distension. ### Surgical Options (Not First-Line Medical Management) - **Hysterectomy (C):** Definitive but irreversible; reserved for completed childbearing with failed medical therapy or severe symptoms. - **Myomectomy via laparotomy (D):** Fertility-preserving surgical option; not a medical management strategy. ### Management Algorithm 1. **Symptomatic fibroids with large uterus + anaemia** → GnRH agonist × 3 months 2. **Reassess:** If anaemia corrected and symptoms improved → consider definitive surgery (hysterectomy or myomectomy) or continue monitoring 3. **LNG-IUD:** Appropriate for mild-to-moderate menorrhagia with small fibroids and normal cavity **Tip:** GnRH agonists are the gold-standard preoperative medical therapy for large symptomatic fibroids. LNG-IUD is preferred for menorrhagia control in smaller fibroids without significant cavity distortion. [cite: ACOG Practice Bulletin No. 228, Uterine Fibroids, 2021; Shaw's Textbook of Gynaecology, 16th ed., Ch. Fibroid Uterus; KD Tripathi Essentials of Medical Pharmacology, GnRH analogues]